Chiasma initiated with a Buy at Roth Capital. Roth Capital analyst Yasmeen Rahimi started coverage of Chiasma with a Buy rating and a $16 price target. With two Phase 3 readouts on the horizon, Chiasma is a “fallen angel” ready to soar back into the acromegaly market, the analyst contends.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.